BCL2L1 and breast carcinoma: As with single-agent BCL-XL inhibition, MCL-1 inhibitors used as monotherapy are only marginally effective in solid tumour-derived cell lines [37] such as patient-derived xenograft (PDX) models of breast cancer [31] and KRAS-mutant NSCLC [40].